Opinion|Videos|January 5, 2024
Approaches for 1L Therapy and Restaging in Triple-Positive mBC
Susan Dent, MD, delves into the exploration of front-line treatment options for triple-positive breast cancer and examines strategies for restaging in the event of disease progression after first-line therapy.
Advertisement
Episodes in this series
Advertisement
Related to this article
Mark Burkard, MD, PhD, discussed genomic gaps, extreme survivors of metastatic breast cancer, and how minimal residual disease testing may refine care.
Hope S. Rugo, MD, discussed KEYNOTE-B49 data showing pembrolizumab plus chemotherapy improved PFS in PD-L1-positive HR+/HER2- breast cancer.
Jan Kitajewski, PhD, discusses how an ancestry-linked blood type may influence triple-negative breast cancer outcomes and clinical trial eligibility.
Black women die from breast cancer at rates 40% higher than white women — and are still missing from the trials that could help. Dr. Coral Omene on why.
The European Commission approved adjuvant T-DXd for HER2-positive early breast cancer with residual invasive disease based on DESTINY-Breast05 data.
Jan Kitajewski, PhD, explains how Notch inhibitors may sustain specialized tumor blood vessels that deliver immune cells and boost immuno-oncology.
In a phase 3 trial, the Breast Cancer Locator was noninferior to wire localization and lowered positive margin rates in nonpalpable breast cancer.
ASCENT-03 subgroup data show sacituzumab govitecan improved PFS vs chemotherapy across subgroups in untreated metastatic TNBC.
Advertisement
Advertisement
Trending on CancerNetwork
1
Closing the Gaps in Precision Oncology for Breast Cancer
2
KEYNOTE-B49 Points to a PD-L1-Defined Subset Benefiting From Immunotherapy in Breast Cancer
3
Navigating PD-L1–Low Gastroesophageal Cancer Treatment and Payer Challenges
4
Managing Patients With No Pathologic Response After Durvalumab Plus FLOT
5